Voyager Therapeutics 3Q 2026: Revenue $4.01M, EPS ($0.4) — 10-Q Summary

Voyager Therapeutics’ collaboration revenue declined year over year in 3Q 2026, while its net loss narrowed. Lower collaboration revenue was partly offset by reduced research and development and general and administrative expenses, reflecting lower VY7523 spending, reduced VY1706 manufacturing costs, portfolio prioritization and lower employee-related expenses.

Financial Highlights

¹ Reported as “Collaboration revenue”. ² Reported as “Net loss”. ³ Reported as “Net loss per share, basic and diluted”.

Business Highlights

• Collaboration revenue: $4.0M, including $3.1M under the 2023 Novartis agreement, $0.5M under the 2019 Neurocrine agreement and $0.4M in other collaboration revenue.
• VY1706: FDA cleared its IND in the second quarter of 2026 and Health Canada cleared its CTA in July; U.S. patient screening is underway.
• VY7523: Enrollment in the Phase 1 multiple ascending dose trial was completed in the fourth quarter of 2025; the last patient visit occurred in October 2026.
• Restructuring: The company recognized approximately $1.4M in charges during the quarter related to a reduction in force to align resources and extend its cash runway.
• Cash runway: Cash, cash equivalents and marketable securities were $132.1M at September 30, 2026; the company expects these resources and collaboration reimbursements to cover planned needs into the second quarter of 2028.

Original SEC Filing: Voyager Therapeutics, Inc. [ VYGR ] - 10-Q - Nov. 05, 2026